Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon

Talitha I. Verhoef; William K. Redekop; Tom Schalekamp; Felix J.M. Van Der Meer; Saskia Le Cessie; Judith A.M. Wessels; Erik Van Meegen; Rianne M.F. Van Schie; Anthonius De Boer; Anke-Hilse Maitland-Van Der Zee

doi:10.1002/pds.2206

Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon

Talitha I. Verhoef, William K. Redekop, Tom Schalekamp, Felix J.M. Van Der Meer, Saskia Le Cessie, Judith A.M. Wessels, Erik Van Meegen, Rianne M.F. Van Schie, Anthonius De Boer, Anke-Hilse Maitland-Van Der Zee

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Meeting Abstract › Other research output

Abstract

Background: The required dose of acenocoumarol (ACE) and phenprocoumon (PHE) and the risk of bleeding or thrombotic events in the initiation period (first month) of these drugs have been found to be associated with CYP2C9 and VKORC1 genotype. Objectives: To investigate the influence of CYP2C9 and VKORC1 polymorphisms on the incidence of over- and underanticoagulation after the initiation period of ACE and PHE. Methods: Patients using either ACE or PHE with a target INR of 2.0-3.5 were included from two anticoagulant clinics in the Netherlands in a retrospective cohort study. In total, 275 ACE users and 486 PHE users were selected for this study, with complete information on INR values from the initiation to the moment of data collection. The relationship between CYP2C9 and VKORC1genotypes and the occurrence of one or more subtherapeutic (≤2) or supratherapeutic (≥3.5) INR values for different periods (0-1, 1-3, 3-6, 6-9, 9-12, 12-15 and 15-18 months) after treatment initiation was investigated using chi-square tests. Results: During the first month of ACE treatment, 21% of the patients with a VKORC1-CC (wildtype) genotype had at least one supratherapeutic INR value, versus 41% and 62% for the CT and TT carriers respectively (p

Original language	English
Pages (from-to)	329
Number of pages	1
Journal	Pharmacoepidemiology and Drug Safety
Volume	20
DOIs	https://doi.org/10.1002/pds.2206
Publication status	Published - 1 Aug 2011

Keywords

acenocoumarol
phenprocoumon
coumarin derivative
anticoagulant agent
risk management
pharmacogenetics
pharmacoepidemiology
international normalized ratio
patient
human
genotype
risk
information processing
chi square test
cohort analysis
allele
bleeding
hospital
Netherlands
wild type

Access to Document

10.1002/pds.2206

Cite this

@article{5b75b7638aca401f964f62efa9df8c42,

title = "Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon",

abstract = "Background: The required dose of acenocoumarol (ACE) and phenprocoumon (PHE) and the risk of bleeding or thrombotic events in the initiation period (first month) of these drugs have been found to be associated with CYP2C9 and VKORC1 genotype. Objectives: To investigate the influence of CYP2C9 and VKORC1 polymorphisms on the incidence of over- and underanticoagulation after the initiation period of ACE and PHE. Methods: Patients using either ACE or PHE with a target INR of 2.0-3.5 were included from two anticoagulant clinics in the Netherlands in a retrospective cohort study. In total, 275 ACE users and 486 PHE users were selected for this study, with complete information on INR values from the initiation to the moment of data collection. The relationship between CYP2C9 and VKORC1genotypes and the occurrence of one or more subtherapeutic (≤2) or supratherapeutic (≥3.5) INR values for different periods (0-1, 1-3, 3-6, 6-9, 9-12, 12-15 and 15-18 months) after treatment initiation was investigated using chi-square tests. Results: During the first month of ACE treatment, 21% of the patients with a VKORC1-CC (wildtype) genotype had at least one supratherapeutic INR value, versus 41% and 62% for the CT and TT carriers respectively (p",

keywords = "acenocoumarol, phenprocoumon, coumarin derivative, anticoagulant agent, risk management, pharmacogenetics, pharmacoepidemiology, international normalized ratio, patient, human, genotype, risk, information processing, chi square test, cohort analysis, allele, bleeding, hospital, Netherlands, wild type",

author = "Verhoef, {Talitha I.} and Redekop, {William K.} and Tom Schalekamp and {Van Der Meer}, {Felix J.M.} and {Le Cessie}, Saskia and Wessels, {Judith A.M.} and {Van Meegen}, Erik and {Van Schie}, {Rianne M.F.} and {De Boer}, Anthonius and {Maitland-Van Der Zee}, Anke-Hilse",

year = "2011",

month = aug,

day = "1",

doi = "10.1002/pds.2206",

language = "English",

volume = "20",

pages = "329",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon

AU - Verhoef, Talitha I.

AU - Redekop, William K.

AU - Schalekamp, Tom

AU - Van Der Meer, Felix J.M.

AU - Le Cessie, Saskia

AU - Wessels, Judith A.M.

AU - Van Meegen, Erik

AU - Van Schie, Rianne M.F.

AU - De Boer, Anthonius

AU - Maitland-Van Der Zee, Anke-Hilse

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background: The required dose of acenocoumarol (ACE) and phenprocoumon (PHE) and the risk of bleeding or thrombotic events in the initiation period (first month) of these drugs have been found to be associated with CYP2C9 and VKORC1 genotype. Objectives: To investigate the influence of CYP2C9 and VKORC1 polymorphisms on the incidence of over- and underanticoagulation after the initiation period of ACE and PHE. Methods: Patients using either ACE or PHE with a target INR of 2.0-3.5 were included from two anticoagulant clinics in the Netherlands in a retrospective cohort study. In total, 275 ACE users and 486 PHE users were selected for this study, with complete information on INR values from the initiation to the moment of data collection. The relationship between CYP2C9 and VKORC1genotypes and the occurrence of one or more subtherapeutic (≤2) or supratherapeutic (≥3.5) INR values for different periods (0-1, 1-3, 3-6, 6-9, 9-12, 12-15 and 15-18 months) after treatment initiation was investigated using chi-square tests. Results: During the first month of ACE treatment, 21% of the patients with a VKORC1-CC (wildtype) genotype had at least one supratherapeutic INR value, versus 41% and 62% for the CT and TT carriers respectively (p

AB - Background: The required dose of acenocoumarol (ACE) and phenprocoumon (PHE) and the risk of bleeding or thrombotic events in the initiation period (first month) of these drugs have been found to be associated with CYP2C9 and VKORC1 genotype. Objectives: To investigate the influence of CYP2C9 and VKORC1 polymorphisms on the incidence of over- and underanticoagulation after the initiation period of ACE and PHE. Methods: Patients using either ACE or PHE with a target INR of 2.0-3.5 were included from two anticoagulant clinics in the Netherlands in a retrospective cohort study. In total, 275 ACE users and 486 PHE users were selected for this study, with complete information on INR values from the initiation to the moment of data collection. The relationship between CYP2C9 and VKORC1genotypes and the occurrence of one or more subtherapeutic (≤2) or supratherapeutic (≥3.5) INR values for different periods (0-1, 1-3, 3-6, 6-9, 9-12, 12-15 and 15-18 months) after treatment initiation was investigated using chi-square tests. Results: During the first month of ACE treatment, 21% of the patients with a VKORC1-CC (wildtype) genotype had at least one supratherapeutic INR value, versus 41% and 62% for the CT and TT carriers respectively (p

KW - acenocoumarol

KW - phenprocoumon

KW - coumarin derivative

KW - anticoagulant agent

KW - risk management

KW - pharmacogenetics

KW - pharmacoepidemiology

KW - international normalized ratio

KW - patient

KW - human

KW - genotype

KW - risk

KW - information processing

KW - chi square test

KW - cohort analysis

KW - allele

KW - bleeding

KW - hospital

KW - Netherlands

KW - wild type

U2 - 10.1002/pds.2206

DO - 10.1002/pds.2206

M3 - Meeting Abstract

SN - 1053-8569

VL - 20

SP - 329

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

ER -

Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon

Abstract

Keywords

Access to Document

Fingerprint

Cite this